All In Biotech

Drug Trial Radar · NCT06203821

Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

A Pilot Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

May 30, 2027

Study completion Sep 30, 2032

Sponsor

Lead sponsor
Aram HezelAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
NETRIS Pharma
First posted
Jan 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to investigate whether adding the study drug, NP137, to a patient's treatment regimen (before surgery and in combination with chemotherapy afterward) can alter the behavior of pancreatic cancer..

Conditions

  • Pancreatic Cancer

Interventions

  • NP137Drug

    NP137 for the Treatment of Resectable Pancreatic Cancer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determining if NP137 can shift the primary tumor MAK's Signature Epithelial-to-Mesenchymal Transition (EMT) Mean Score towards a more epithelial phenotypeTime frame: 3-5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Rochester

    Rochester, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.